Reach for Zen.
Reach for Zenrelia™ (ilunocitinib tablets).
Zenrelia is the innovative, once-daily treatment that offers dogs relief from itchy and irritated skin caused by allergic and atopic dermatitis.
Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Highly rated by vets and dog owners1
Zenrelia aims to get your dog back to normal*
Treatment you can turn to when your dog has itchy skin.
Zenrelia is the innovative, once-daily treatment that offers dogs relief from itchy and irritated skin – from day one.
As well as improving red, inflamed skin, Zenrelia can reduce your dog’s itch back to just the normal*, occasional good scratch – and lets them get back to being themselves.
Zen is within your reach
Hypoallergenic, unflavored oral treatment
Given once a day, from the comfort of home
With or without food
Rebates
Save when purchasing Zenrelia. Redeem $9 off a 30-count and $20 off 90-count.
Product brochure and itch tracker
Read the brochure and use our itch tracker to monitor your dog's progress.
Stay informed on everything Zenrelia
INDICATIONS
Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age.
IMPORTANT SAFETY INFORMATION
See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1-888-545-5973 or visit www.elancolabels.com/us/zenrelia.
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog’s vaccine schedule with your veterinarian. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.
